share_log

Vivos Therapeutics | CORRESP: CORRESP

Vivos Therapeutics | CORRESP: CORRESP

Vivos Therapeutics | CORRESP:信函
美股sec公告 ·  04/24 12:56
Moomoo AI 已提取核心信息
Vivos Therapeutics, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form S-1, initially filed on April 9, 2024. The company seeks to have the registration become effective at 4:30 p.m. on April 26, 2024. This request was made under Rule 461 of the Securities Act of 1933, as amended. Additionally, Vivos Therapeutics has authorized Lawrence A. Rosenbloom, Esq. of Ellenoff Grossman & Schole LLP to communicate with the SEC staff regarding any potential deferral of the new effective time.
Vivos Therapeutics, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form S-1, initially filed on April 9, 2024. The company seeks to have the registration become effective at 4:30 p.m. on April 26, 2024. This request was made under Rule 461 of the Securities Act of 1933, as amended. Additionally, Vivos Therapeutics has authorized Lawrence A. Rosenbloom, Esq. of Ellenoff Grossman & Schole LLP to communicate with the SEC staff regarding any potential deferral of the new effective time.
Vivos Therapeutics, Inc.已正式要求美国证券交易委员会(SEC)加快其最初于2024年4月9日提交的S-1表格注册声明的生效。该公司希望注册于2024年4月26日下午4点30分生效。该请求是根据经修订的1933年《证券法》第461条提出的。此外,Vivos Therapeutics已授权埃伦诺夫·格罗斯曼和斯科尔律师事务所的劳伦斯·罗森布鲁姆先生就新生效时间的任何可能延期与美国证券交易委员会工作人员进行沟通。
Vivos Therapeutics, Inc.已正式要求美国证券交易委员会(SEC)加快其最初于2024年4月9日提交的S-1表格注册声明的生效。该公司希望注册于2024年4月26日下午4点30分生效。该请求是根据经修订的1933年《证券法》第461条提出的。此外,Vivos Therapeutics已授权埃伦诺夫·格罗斯曼和斯科尔律师事务所的劳伦斯·罗森布鲁姆先生就新生效时间的任何可能延期与美国证券交易委员会工作人员进行沟通。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息